Komori
Share Issuance and Disposal4888STELLA PHARMA CORPORATIONPharmaceuticals

Notice of Completion of Payment for New Shares and Stock Acquisition Rights Issued by Way of Third-Party Allotment in the Third Issuance under the Share and Stock Acquisition Rights Issuance Program Agreement

The issuance of 1,000,000 new shares and allocation of 10,500 stock acquisition rights under the third-party allotment No. 3 have been completed, and payment has been made.

Worth reading
54Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
299000000
Yen (proceeds from the issuance of new shares)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Issuance of new shares and stock acquisition rights through a third-party allotment

Who receives how much

New shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights 1,050,000 shares (10,500 stock acquisition rights; 100 shares per stock acquisition right)

CVI Investments, Inc.1,000,000 new shares and 1,050,000 underlying shares

The lower thin line represents the existing number of shares to which these shares will be added.

New shares ¥299 per share / Stock Acquisition Rights ¥194 per Stock Acquisition Right
Total issue value

New shares ¥299,000,000 / Stock Acquisition Rights ¥2,037,000

Amount of funds to be raised
¥299,000,000 from the issuance of new shares. ¥479,787,000 from the issuance of stock acquisition rights (breakdown: ¥2,037,000 from the issuance of stock acquisition rights and ¥477,750,000 from the exercise of stock acquisition rights). The estimated net proceeds are Not disclosed.
Terms of the stock acquisition rights
Exercise price
¥455 per share. The adjustment provisions and adjustment floor are Not disclosed.
Exercise period
From 1 September 2026 to 31 August 2030
Number of Stock Acquisition Rights
Total number issued: 10,500. Outstanding unexercised balance: Not disclosed.
Payment date
31 August 2026
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of new shares and stock acquisition rights through a third-party allotment
Number of shares to be issued or disposed ofNew shares 1,000,000 common shares / Potential shares underlying the stock acquisition rights 1,050,000 shares (10,500 stock acquisition rights; 100 shares per stock acquisition right)
Issue price and disposal priceNew shares ¥299 per share / Stock Acquisition Rights ¥194 per Stock Acquisition Right
Total issue valueNew shares ¥299,000,000 / Stock Acquisition Rights ¥2,037,000
Amount of funds to be raised¥299,000,000 from the issuance of new shares. ¥479,787,000 from the issuance of stock acquisition rights (breakdown: ¥2,037,000 from the issuance of stock acquisition rights and ¥477,750,000 from the exercise of stock acquisition rights). The estimated net proceeds are Not disclosed.
Payment date31 August 2026
Intended allotteeName CVI Investments, Inc. / Number of Shares 1,000,000 new shares and 1,050,000 underlying shares
Exercise price¥455 per share. The adjustment provisions and adjustment floor are Not disclosed.
Exercise periodFrom 1 September 2026 to 31 August 2030
Number of Stock Acquisition RightsTotal number issued: 10,500. Outstanding unexercised balance: Not disclosed.
Items this document does not state (18)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The prescribed payment procedures for the third-party allotment No. 3 announced on 13 August 2026 have been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of Payment for New Shares and Stock Acquisition Rights Issued by Way of Third-Party Allotment in the Third Issuance under the Share and Stock Acquisition Rights Issuance Program Agreement | STELLA PHARMA CORPORATION (4888) timely disclosure | Komori